Acalabrutinib study in Indian patients with chronic lymphocytic leukaemia & relapsed and refractory mantle cell lymphoma

Trial Identifier: D8220C00022
Sponsor: AstraZeneca
NCTID:: NCT04930536
Start Date: July 2021
Primary Completion Date: May 2023
Study Completion Date: May 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations